Document is current

Article History

First Online: 3 April 2025

Conflict of interest

: F. Siebenhaar has received research funding from and/or is or has recently been a speaker/consultant for Allakos, Blueprint, Celldex, Cogent, Escient, GSK, Granular, Invea, Moxie, Noucor, Novartis, Sanofi/Regeneron, Telios and ThirdHarmonicBio. R. Brehler was speaker and consultant for: AeDA, ALK, Allergopharma, Apothekerkammer Westfalen-Lippe, Astra Zeneca, Behring, Bencard, BVDD, Coglitando, DGP, DIATER, ECM Expo&Conference Management GmbH, Mein Allergie Portal, Forum für med. Fortbildung FomF GmbH, GSK, HAL, Leti, Lilly, MedUpdate, Merck, Novartis, RG-Gesellschaft für Information und Organization mbH, Sanofi, Stallergenes Greer, Takeda, Thermo-Fischer and med update GmbH. R. Brehler has been involved in clinical studies for ALK; Allergopharma, Bencard, Biotech Tools, Circassia, Genentech, Novartis and Stallergenes Greer. D. Christen has received research funding (to the institution) from and/or is or has recently been a speaker/consultant for Astra Zeneca, BeiGene, Blueprint, Novartis and Pfizer. K. Hartmann is or has recently been a speaker/consultant for ALK, Allergopharma, Almirall, BioCryst, Blueprint, Cogent, Galderma, KalVista, Leo, Menarini, Novartis, Pfizer, Sanofi, Takeda and ThermoFisher. S. Altrichter has received funding for clinical trials/research and/or served as an honorary speaker for Allakos, AstraZeneca, ALK, Biocryst, Blueprint, Celltrion, CSL Behring, Kalvista, LEOPharma, Moxie, Novartis, Phavaris, Sanofi, Takeda and ThermoFisher. C. Lang has received research grants and/or has recently been a speaker for AbbVie, Amgen, Blueprint, Galderma, Incyte, Leo Pharma, Novartis, Pfizer, Sanofi and ThermoFisher. U. Lippert was a consultant, speaker or researcher (received grants and/or was involved in clinical trials) for AbbVie, ALK-Abéllo, Almirall, Blueprint, CSL Behring, Leo Pharma, Lilly, Meda Pharma, Novartis, Janssen-Cilag, RG-Gesellschaft für Information und Organization mbH, Sanofi-Regeneron and Shire/Takeda. J. Panse has received research funding (for the institution) from and/or is or was recently a speaker/consultant for Blueprint, Cogent, Novartis, Sanofi and Telios. P. Pyatilova has received research funding from and/or is or was recently a consultant/advisor for Allakos, Blueprint, Celldex, GSK, Granular and ThirdHarmonicBio. P. Schmid-Grendelmeier has received lecture honoraria from Novartis, AbbVie, AstraZeneca Janssen, LEO and research funding from the LEO Foundation. P. Staubach has received research funding from and/or is or has recently been a speaker/consultant for Blueprint, Celltrion, Novartis, Sanofi, Regeneron, Pharvaris, CSL and Kalvista. S. Röseler has received lecture fees from Bencard, Leti and Allergopharma and has been a consultant for Sidroga, GSK, Novartis and Sanofi. F. Ruëff has received honorary speaker fees for ALK-Abelló, Blueprint, BoehringerIngelheim, Novartis, ThermoFisher and UCB. N. Wagner has recently been a speaker or consultant for ALK-Abelló, Novartis, Takeda, Blueprint, CSL-Behring, Biocryst, Synlab and Nutricia and has received research funding from Novartis. D. von Bubnoff was a consultant for Novartis and Regeneron. N. von Bubnoff was a consultant for Blueprint, Cogent and Novartis. T. Zuberbier reports speaking fees from Amgen, AstraZeneca, AbbVie, ALK-Abelló, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES Farma, HAL Allergie GmbH, Henkel, Kryolan, Leti, L’Oreal, Meda, Menarini, Merck Sharp & Dohme, Novartis, Nuocor, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB and Uriach; he received fees for industry consulting from Abivax, Almirall, Blueprint, Celldex, Celltrion, Novartis and Sanofi. L. Klimek is editor-in-chief of Allergo Journal and Allergo Journal International and President of the German Society of Allergy AeDA. K. Brockow has received research funding from and/or is or has recently been a speaker/consultant for Allakos, Blueprint, Celldex, Novartis, ThermoFisher, HAL, Syneos and ALK. N. Mülleneisen, M. Joest, H. Ott, M. Maurer, F. Bärhold and K. aufm Kampe declare that there are no conflicts of interest.